 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 11 | 14 | | 1996 | 6 | 13 | 19 | | 1997 | 5 | 5 | 10 | | 1998 | 2 | 14 | 16 | | 1999 | 7 | 7 | 14 | | 2000 | 6 | 9 | 15 | | 2001 | 10 | 15 | 25 | | 2002 | 7 | 16 | 23 | | 2003 | 8 | 11 | 19 | | 2004 | 12 | 17 | 29 | | 2005 | 16 | 14 | 30 | | 2006 | 17 | 12 | 29 | | 2007 | 20 | 12 | 32 | | 2008 | 13 | 21 | 34 | | 2009 | 37 | 20 | 57 | | 2010 | 26 | 21 | 47 | | 2011 | 13 | 18 | 31 | | 2012 | 11 | 14 | 25 | | 2013 | 14 | 10 | 24 | | 2014 | 32 | 9 | 41 | | 2015 | 10 | 9 | 19 | | 2016 | 14 | 13 | 27 | | 2017 | 20 | 14 | 34 | | 2018 | 19 | 8 | 27 | | 2019 | 18 | 8 | 26 | | 2020 | 21 | 11 | 32 | | 2021 | 16 | 8 | 24 | | 2022 | 6 | 24 | 30 | | 2023 | 5 | 18 | 23 | | 2024 | 13 | 12 | 25 | | 2025 | 7 | 2 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Fahey CC, Clark-Garvey S, Porten S, Kamat AM, Flaig TW, Taylor JA, Kim WY, Milowsky MI. Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. Curr Oncol. 2025 May 14; 32(5).
-
Wang Y, Hanford A, Boroumand M, Kalonia C, Leissa J, Shah M, Pham T, Randolph T, Prajapati I. Assessing subvisible particle risks in monoclonal antibodies: insights from quartz crystal microbalance with dissipation, machine learning, and in silico analysis. MAbs. 2025 Dec; 17(1):2501629.
-
van Rossum M, Veuskens BRJ, Brouwer MC, van Mierlo G, Lucientes-Continente L, Goicoechea de Jorge E, Uzonyi B, Matola AT, J?zsi M, M?ller G, Meter-Arkema AM, Poppelaars F, Pauly D, Pouw RB, Toonen EJM. Development and Characterization of Novel ELISAs for the Specific Quantification of the Factor H-Related Proteins 2, 3, 4, and 5. J Innate Immun. 2025; 17(1):226-243.
-
Rudy MJ, Wilson CJ, Hinckley B, Baker DC, Royal JM, Hoke MP, Brennan MB, Vogt MR, Clarke P, Tyler KL. EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis. mBio. 2025 Apr 09; 16(4):e0390624.
-
Alexis A, McMichael A, Vashi N, Bhutani T, Rodriguez AO, Yeung J, Choi O, Chan D, Alkousakis T, Bronner DN, Park-Wyllie L, Gao LL, Grimes P, Shahriari M, Yadav G, Kindred C, Taylor SC, Desai SR. Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement. JAMA Dermatol. 2025 Mar 01; 161(3):256-264.
-
Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, Bone F, Purdue L, Yin DE, Moye J, Spiegel HML, Majji S, Theron GB, Mujuru HA, Purswani M, Alvarez G, Deville JG, Chambers C, Brown E, Harding PA, Tobin NH, Low K, Gama L. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1. J Pediatric Infect Dis Soc. 2025 Feb 06; 14(2).
-
Mourad A, Grandits GA, Siegel LK, Engen N, Barkauskas C, Eriobu N, Jain MK, Jensen TO, Ginde A, Higgs E, Knox DB, Kitonsa J, Kim K, Malin JJ, Rapti V, Price DA, Mena Lora AJ, Mathews G, Mylonakis E, Murray TA, Sandkovsky U, Paredes R, Ramachandruni S, Reilly C, Vock D, Williamson JC, Young BE, Self WH, Lundgren J, Holland TL. Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial. Clin Microbiol Infect. 2025 Jun; 31(6):1053-1060.
-
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 May; 36(5):583-591.
-
Szefler S, Corren J, Silverberg JI, Okragly A, Sun Z, Natalie CR, Zitnik R, Siu K, Blauvelt A. Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II). Immunotherapy. 2024; 16(20-22):1211-1216.
-
Martin CK, Wan JJ, Yin P, Morrison TE, Messer WB, Rivera-Amill V, Lai JR, Grau N, Rey FA, Couderc T, Lecuit M, Kielian M. The alphavirus determinants of intercellular long extension formation. mBio. 2025 Feb 05; 16(2):e0198624.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|